OR WAIT null SECS
© 2022 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2022 MJH Life Sciences™ and Formulary Watch. All rights reserved.
August 09, 2022
The approval had been delayed as the regulatory agency reviewed data on Myfembree's impact on bone mineral density.
August 08, 2022
Nubeqa, in combination with docetaxel, is now approved to treat metastatic prostate cancer.
August 06, 2022
The tablet form has the same safety and efficacy as the capsule formulation and allows it to be administered with gastric-reducing therapies.
August 05, 2022
This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype. Its approval comes four months ahead of its PDUFA action date.
The committee will meet on Sept. 7, 2022, to discuss additional analyses of data from the Amylyx’s clinical studies. The updated PDUFA goal date is Sept. 29, 2022.
The FDA has requested Acadia conduct an additional trial of Nuplazid to support an indication in patients with Alzheimer’s disease.
August 04, 2022
Fresenius Kabi expects to receive FDA approval for its tocilizumab biosimilar in 2023 and is seeking approval in both intravenous and subcutaneous administration.
August 03, 2022
OptumRx profiles four therapies that are expecting FDA decisions in the next few months.
Coherus’ Cimerli has been approved to be interchangeable for all five indications, including age-related macular degeneration and diabetic retinopathy. It will be available in early October 2022.
August 01, 2022
Stelara is the first biologic targeting both cytokines IL-12 and IL-23 and offers a therapeutic option for children six years of age and older living with active psoriatic arthritis, a rare disease.